[1]徐鹏卫,代克强,卢建国,等.流行性感冒防控新策略研究进展[J].新乡医学院学报,2017,34(11):955-959.[doi:10.7683/xxyxyxb.2017.11.001]

点击复制

流行性感冒防控新策略研究进展

分享到：

参考文献/References:

［1］　COX N J，SUBBARAO K.Global epidemiology of influenza：past and present［J］.Annu Rev Med，2000，51：407-421.
［2］　GAMBLIN S J，SKEHEL J J.Influenza hemagglutinin and neuraminidase membrane glycoproteins［J］.J Biol Chem，2010，285（37）：28403-28409.
［3］　ESTE J A，TELENTI A.HIV entry inhibitors［J］.Lancet，2007，370（9581）：81-88.
［4］　HU J，ROBINSON J L.Treatment of respiratory syncytial virus with palivizumab：a systematic review［J］.World J Pediatr，2010，6（4）：296-300.
［5］　MATTHEWS T，SALGO M，GREENBERG M，et al.Enfuvirtide：the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes［J］.Nat Rev Drug Discov，2004，3（3）：215-225.
［6］　EKIERT D C，KASHYAP A K，STEEL J，et al.Cross-neutralization of influenza A viruses mediated by a single antibody loop［J］.Nature，2012，489（7417）：526-532.
［7］　YOSHIDA R，IGARASHI M，OZAKI H，et al.Cross-protective potential of a novel monoclonal antibody directed against antigenic site B of the hemagglutinin of influenza A viruses［J］.PLoS Pathog，2009，5（3）：e1000350.
［8］　JONES J C，TURPIN E A，BULTMANN H，et al.Inhibition of influenza virus infection by a novel antiviral peptide that targets viral attachment to cells［J］.J Virol，2006，80（24）：11960-11967.
［9］　NICOL M Q，LIGERTWOOD Y，BACON M N，et al.A novel family of peptides with potent activity against influenza A viruses［J］.J Gen Virol，2012，93（Pt 5）：980-986.
［10］　LAKADAMYALI M，RUST M J，ZHUANG X.Endocytosis of influenza viruses［J］.Microbes Infect，2004，6（10）：929-936.
［11］　HARRISON S C.Viral membrane fusion［J］.Nat Struct Mol Biol，2008，15（7）：690-698.
［12］　YU K L，TORRI A F，LUO G，et al.Structure-activity relationships for a series of thiobenzamide influenza fusion inhibitors derived from 1，3，3-trimethyl-5-hydroxy-cyclohexylmethylamine［J］.Bioorg Med Chem Lett，2002，12（23）：3379-3382.
［13］　ZHU L，LI Y，LI S，et al.Inhibition of influenza A virus （H1N1） fusion by benzenesulfonamide derivatives targeting viral hemagglutinin［J］.PLoS One，2011，6（12）：e29120.
［14］　THROSBY M，VAN DEN BRINK E，JONGENEELEN M，et al.Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM⁺ memory B cells［J］.PLoS One，2008，3（12）：e3942.
［15］　DREYFUS C，LAURSEN N S，KWAKS T，et al.Highly conserved protective epitopes on influenza B viruses［J］.Science，2012，337（6100）：1343-1348.
［16］　MATROSOVICH M N，MATROSOVICH T Y，GRAY T，et al.Human and avian influenza viruses target different cell types in cultures of human airway epithelium［J］.Proc Natl Acad Sci USA，2004，101（13）：4620-4624.
［17］　RUSSELL R J，HAIRE L F，STEVENS D J，et al.The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design［J］.Nature，2006，443（7107）：45-49.
［18］　GUBAREVA L V，KAISER L，HAYDEN F G.Influenza virus neuraminidase inhibitors［J］.Lancet，2000，355（9206）：827-835.
［19］　VON ITZSTEIN M，WU W Y，KOK G B，et al.Rational design of potent sialidase-based inhibitors of influenza virus replication［J］.Nature，1993，363（6428）：418-423.
［20］　TSANG K W，ENG P，LIAM C K，et al.H5N1 influenza pandemic：contingency plans［J］.Lancet，2005，366（9485）：533-534.
［21］　DAVIES B E.Pharmacokinetics of oseltamivir：an oral antiviral for the treatment and prophylaxis of influenza in diverse populations［J］.J Antimicrob Chemother，2010，65 （Suppl 2）：ii5-ii10.
［22］　KOHNO S，KIDA H，MIZUGUCHI M，et al.Intravenous peramivir for treatment of influenza A and B virus infection in high-risk patients［J］.Antimicrob Agents Chemother，2011，55（6）：2803-2812.
［23］　KOYAMA K，TAKAHASHI M，OITATE M，et al.CS-8958，a prodrug of the novel neuraminidase inhibitor R-125489，demonstrates a favorable long-retention profile in the mouse respiratory tract［J］.Antimicrob Agents Chemother，2009，53（11）：4845-4851.
［24］　SAMSON M，PIZZORNO A，ABED Y，et al.Influenza virus resistance to neuraminidase inhibitors［J］.Antiviral Res，2013，98（2）：174-185.
［25］　FENG E，YE D，LI J，et al.Recent advances in neuraminidase inhibitor development as anti-influenza drugs［J］.Chem Med Chem，2012，7（9）：1527-1536.
［26］　WEIGHT A K，HALDAR J，ALVAREZ DE CIENFUEGOS L，et al.Attaching zanamivir to a polymer markedly enhances its activity against drug-resistant strains of influenza A virus［J］.J Pharm Sci，2011，100（3）：831-835.
［27］　PINTO L H，LAMB R A.The M2 proton channels of influenza A and B viruses［J］.J Biol Chem，2006，281（14）：8997-9000.
［28］　ITO T，GORMAN O T，KAWAOKA Y，et al.Evolutionary analysis of the influenza A virus M gene with comparison of the M1 and M2 proteins［J］.J Virol，1991，65（10）：5491-5498.
［29］　WANG C，TAKEUCHI K，PINTO L H，et al.Ion channel activity of influenza A virus M2 protein：characterization of the amantadine block［J］.J Virol，1993，67（9）：5585-5594.
［30］　MOSS R B，DAVEY R T，STEIGBIGEL R T，et al.Targeting pandemic influenza：a primer on influenza antivirals and drug resistance［J］.J Antimicrob Chemother，2010，65（6）：1086-1093.
［31］　WANG J，WU Y，MA C，et al.Structure and inhibition of the drug-resistant S31N mutant of the M2 ion channel of influenza A virus［J］.Proc Natl Acad Sci USA，2013，110（4）：1315-1320.
［32］　WANG J，MA C，FIORIN G，et al.Molecular dynamics simulation directed rational design of inhibitors targeting drug-resistant mutants of influenza A virus M2［J］.J Am Chem Soc，2011，133（32）：12834-12841.
［33］　BALANNIK V，WANG J，OHIGASHI Y，et al.Design and pharmacological characterization of inhibitors of amantadine-resistant mutants of the M2 ion channel of influenza A virus［J］.Biochemistry，2009，48（50）：11872-11882.
［34］　WEI G，MENG W，GUO H，et al.Potent neutralization of influenza A virus by a single-domain antibody blocking M2 ion channel protein［J］.PLoS One，2011，6（12）：e28309.
［35］　YE Q，GUU T S，MATA D A，et al.Biochemical and structural evidence in support of a coherent model for the formation of the double-helical influenza A virus ribonucleoprotein［J］.Mbio，2012，4（1）：e00467-00412.
［36］　CHENAVAS S，ESTROZI L F，SLAMA-SCHWOK A，et al.Monomeric nucleoprotein of influenza A virus［J］.PLoS Pathog，2013，9（3）：e1003275.
［37］　AMORIM M J，KAO R Y，DIGARD P.Nucleozin targets cytoplasmic trafficking of viral ribonucleoprotein-Rab11 complexes in influenza A virus infection［J］.J Virol，2013，87（8）：4694-4703.
［38］　LEJAL N，TARUS B，BOUGUYON E，et al.Structure-based discovery of the novel antiviral properties of naproxen against the nucleoprotein of influenza A virus［J］.Antimicrob Agents Chemother，2013，57（5）：2231-2242.
［39］　HAO L，SAKURAI A，WATANABE T，et al.Drosophila RNAi screen identifies host genes important for influenza virus replication［J］.Nature，2008，454（7206）：890-893.
［40］　ZHIRNOV O P，MATROSOVICH T Y，MATROSOVICH M N，et al.Aprotinin，a protease inhibitor，suppresses proteolytic activation of pandemic H1N1v influenza virus［J］.Antivir Chem Chemother，2011，21（4）：169-174.
［41］　MALAKHOV M P，ASCHENBRENNER L M，SMEE D F，et al.Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection［J］.Antimicrob Agents Chemother，2006，50（4）：1470-1479.
［42］　MOSS R B，HANSEN C，SANDERS R L，et al.A phase II study of DAS181，a novel host directed antiviral for the treatment of influenza infection［J］.J Infect Dis，2012，206（12）：1844-1851.
［43］　TAKEDA M，LESER G P，RUSSELL C J，et al.Influenza virus hemagglutinin concentrates in lipid raft microdomains for efficient viral fusion［J］.Proc Natl Acad Sci USA，2003，100（25）：14610-14617.
［44］　WANG X，HINSON E R，CRESSWELL P.The interferon-inducible protein viperin inhibits influenza virus release by perturbing lipid rafts［J］.Cell Host Microbe，2007，2（2）：96-105.
［45］　TAN K S，NG W C，SEET J E，et al.Investigating the efficacy of pamidronate，a chemical inhibitor of farnesyl pyrophosphate synthase，in the inhibition of influenza virus infection in vitro and in vivo［J］.Mol Med Rep，2014，9（1）：51-56.
［46］　GARCIA-SASTRE A.Lessons from lipids in the fight against influenza［J］.Cell，2013，154（1）：22-23.
［47］　TAM V C，QUEHENBERGER O，OSHANSKY C M，et al.Lipidomic profiling of influenza infection identifies mediators that induce and resolve inflammation［J］.Cell，2013，154（1）：213-227.
［48］　LEVY B D，KOHLI P，GOTLINGER K，et al.Protectin D1 is generated in asthma and dampens airway inflammation and hyperresponsiveness［J］.J Immunol，2007，178（1）：496-502.
［49］　SERHAN C N.Resolution phase of inflammation：novel endogenous anti-inflammatory and proresolving lipid mediators and pathways［J］.Annu Rev Immunol，2007，25：101-137.
［50］　MORITA M，KUBA K，ICHIKAWA A，et al.The lipid mediator protectin D1 inhibits influenza virus replication and improves severe influenza［J］.Cell，2013，153（1）：112-125.
［51］　MARJUKI H，ALAM M I，EHRHARDT C，et al.Membrane accumulation of influenza A virus hemagglutinin triggers nuclear export of the viral genome via protein kinase Calpha-mediated activation of ERK signaling［J］.J Biol Chem，2006，281（24）：16707-16715.
［52］　HAASBACH E，HARTMAYER C，PLANZ O.Combination of MEK inhibitors and oseltamivir leads to synergistic antiviral effects after influenza A virus infection in vitro［J］.Antiviral Res，2013，98（2）：319-324.
［53］　NENCIONI L，DE CHIARA G，SGARBANTI R，et al.Bcl-2 expression and p38MAPK activity in cells infected with influenza A virus：impact on virally induced apoptosis and viral replication［J］.J Biol Chem，2009，284（23）：16004-16015.
［54］　LOREGIAN A，PALU G.How academic labs can approach the drug discovery process as a way to synergize with big pharma［J］.Trends Microbiol，2013，21（6）：261-264.